Michael Kauffman, M.D., Ph.D.

Michael Kauffman, M.D., Ph.D.

President of DevelopmentatVerastem· In proxies 2023–2025

Pay in FY2025Verastem stock +49.3% the same year

Michael Kauffman, M.D., Ph.D. was paid $273.0K in FY2025 (Dec). Verastem stock rose 49.3% that year.

Pay$100 in the stock at the end of FY23 → $95
Pay is from the Summary Compensation Table of each Verastem proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. VerastemPublic company · 3 yr
    • President of Development2023 – Present · 3 yrStock in role +148%
  2. Adicet Bio, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. BiVictriX Therapeutics PlcPublic company
    • Director? – PresentNo stock prices for these years
  4. Kezar BiosciencesPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • VerastemDirector · 13 yr on the boardNot independentResearch and Development—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?